Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | IDE | P14735 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258645 | 0.84 | CCR4 (0.45) | CCR4MEN1KMT2ANOS1NOS2 | |
| SCHEMBL16258760 | 0.83 | CCR4 (0.44) | CCR4MEN1KMT2ANOS1NOS2 | |
| SCHEMBL18534003 | 0.81 | KMT2A (0.45) | MEN1KMT2ANOS1NOS2TSHR | |
| SCHEMBL11819377 | 0.79 | MEN1 (0.61) | MEN1KMT2ATSHRIDEMAPT | |
| SCHEMBL16241952 | 0.78 | CCR4 (0.80) | CCR4 | |
| SCHEMBL16241953 | 0.78 | CCR4 (0.80) | CCR4 | |
| SCHEMBL16258707 | 0.78 | CCR4 (0.55) | CCR4 | |
| SCHEMBL16258638 | 0.78 | ALDH1A1 (0.57) | CCR4MEN1KMT2ATSHRMAPT | |
| SCHEMBL16242203 | 0.77 | CCR4 (0.63) | CCR4 | |
| SCHEMBL16242204 | 0.77 | CCR4 (0.63) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493453-B2 | Piperazinyl pyrimidine derivatives, preparation method and use thereof | The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China (CN) | 2016-11-15 | — | — | US | disclosed |
| US-9493453-B2 | Piperazinyl pyrimidine derivatives, preparation method and use thereof | The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China (CN) | 2016-11-15 | — | — | US | disclosed |
| US-20150126500-A1 | PIPERAZINYL PYRIMIDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126500-A1 | PIPERAZINYL PYRIMIDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2015-05-07 | — | — | US | disclosed |
| EP-2805947-A1 | PIPERAZINYL PYRIMIDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2014-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126500-A1 | PIPERAZINYL PYRIMIDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | CCR4, CCR1, CCR3 | CCR4 1/4885MEN1 4570/4885KMT2A 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.